November 16, 2017
Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day |
November 13, 2017
Voyager Therapeutics to Present at Investor Conferences in November |
November 12, 2017
Voyager Therapeutics to Host R&D Day on November 16, 2017 |
November 10, 2017
Voyager Therapeutics Announces Closing of Public Offering of Common Stock |
November 07, 2017
Voyager Therapeutics Announces Pricing of Public Offering of Common Stock |
November 06, 2017
Voyager Therapeutics Announces Proposed Offering of Common Stock |
November 02, 2017
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights |
October 30, 2017
Voyager Therapeutics Announces Update to Parkinson’s Disease Program |
October 30, 2017
Voyager Therapeutics to Host Third Quarter 2017 Financial Results and Corporate Highlights Conference Call |
October 17, 2017
Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of Gene and Cell Therapy |
October 06, 2017
Voyager Therapeutics Announces Multiple Data Presentations at the Congress of the European Society of Gene and Cell Therapy |
October 03, 2017
Voyager Therapeutics to Present at Investor Conferences in October |
September 18, 2017
Voyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer |
September 06, 2017
Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease |
August 30, 2017
Voyager Therapeutics to Participate in September Investor Conferences |
August 08, 2017
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights |
August 02, 2017
Voyager Therapeutics to Host Second Quarter 2017 Financial Results and Corporate Highlights Conference Call |
July 17, 2017
Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain |
June 26, 2017
Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease |
June 02, 2017
Voyager Therapeutics to Attend Upcoming Investor Conferences |
June 01, 2017
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease |
May 09, 2017
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights |
May 04, 2017
Voyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call |
April 25, 2017
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease |
March 15, 2017
Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights |
March 08, 2017
Voyager Therapeutics to Host Fourth Quarter and Full Year 2016 Financial Results Conference call |
February 28, 2017
Voyager Therapeutics Supports Rare Disease Day® and Global Movement to Raise Awareness for Rare Diseases |
February 13, 2017
Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS) |
February 02, 2017
Voyager Therapeutics to Attend Upcoming Investor Conferences |
January 25, 2017
Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience |
January 20, 2017
Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease |
January 05, 2017
Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors |
January 03, 2017
Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer |
